HK 003
Alternative Names: HK-003Latest Information Update: 06 Jun 2022
At a glance
- Originator Hefei HankeMab Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 May 2022 Hefei HankeMab Biotechnology has patent protection for HK 003 (Hefei HankeMab Biotechnology website, May 2022)